Effect of intraperitoneal NSC transplantation on the clinical course of EAE.

<p>C57Bl/6 mice were immunized with recombinant myelin oligodendrocyte glycoprotein and treated with intraperitoneal injections of NSCs on days 8, 10 and 12 post immunization. (A) EAE mice received 1×10⁶ SVZ-NSCs or MEFs. Data are expressed as the mean clinical score ± SEM (n = 5 mice). (B) EAE mice received 5×10⁶ GS-N cells or 46C-NS cells. Data are expressed as the mean clinical score ± SEM (n = 9–10 mice). Arrows indicate days of injection. (C–K) Representative spinal cord sections of PBS control mice (C–E), GS-N cell-treated mice (F–H), or 46C-NS cell-treated mice (I–K) were stained with haematoxylin and eosin, luxol fast blue and Bielschowsky silver stain to detect inflammation, demyelination and axonal damage, respectively. Magnification ×400. (L) Proliferative response of splenic T-cells from cell-treated mice and controls to rMOG and non-specific mitogens expressed as the mean counts per minute (CPM). (M–R) Supernatant from rMOG-stimulated splenocyte cultures were collected after 48 hrs and cytokines were quantified by cytometric bead array. (S) Serum rMOG-specific antibody response from NSC-treated mice and controls. Data are expressed as the mean ± SEM (n = 9–10 mice). *P&lt;0.05, **P&lt;0.01, ∧P&lt;0.001 versus PBS controls, ^#P&lt;0.05.